The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Phase I follow-up results for CYP-001, a mesenchymal stem cell product for steroid-refractory acute GvHD
Positive results were announced today for the phase I trial (NCT02923375) of CYP-001, the first commercially developed mesenchymal stem cell product available.1 The primary endpoints of this trial were the safety and efficacy of CYP-001 in adults with steroid-refractory acute graft-versus-host disease (SRaGvHD). The secondary endpoints were complete response, partial response, and overall survival (OS) at Days 28 and 100. The initial evaluation of this multicenter, non-randomized study showed favorable results, with a CR rate of 53% and an OS of 87% at Day 100.
The follow-up results, obtained from 15 patients included in this trial, showed that the OS rate was 60% after 2 years, which compared favorably to historic controls: 1- or 2-year OS ranged from 17%−40% in previous studies. No safety concerns or serious treatment-related adverse events were recorded.
Allogeneic mesenchymoangioblast-derived mesenchymal stem cells make up the active agent of CYP-001. These cells are derived from induced pluripotent stem cells. CYP-001 will be advanced into a phase II trial for SR-GvHD, COVID-19, and critical limb ischemia, and a phase III trial for osteoarthritis.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content